In a continuous endeavor to pursue clinical excellence, Makati Medical Center recently signed a memorandum of agreement with multi-award winning contract research organization (CRO) Novotech Pty Ltd. to engage in global clinical trials.
The collaboration aims to further the research studies that would advance medical care in the country. MakatiMed’s investigators composed of doctors and scientists will participate in the studies managed by Novotech. The premiere hospital will work closely with the organization to deliver high quality results and promote capabilities in clinical trials at industry conferences and events.
Novotech is a leading regional full-service CRO with on-the-ground operations in Australia, New Zealand, South Korea, China, Taiwan, India, Singapore, and Hong Kong among others. It has extensive therapeutic area experience in handling clinical studies with biotechnology companies.
The first clinical trial under the two institutions MOU, which is a study on Paroxysmal Nocturnal Hemoglobinuria that is a rare chronic disease of the blood, is set to begin in the third quarter of the year. The investigator of the study is Teresita E. Dumagay, MD of MakatiMeds Center for Regenerative Medicine.
This collaboration is a great venue for us to promote the hospitals research capabilities, said Johnny B. Sinon, MD, MakatiMed Medical Director. We want MakatiMed to be a working clinical trial site that would pave the way for medical breakthroughs, fueled by our strong interest in medical research.
Representing MakatiMed was Dr. Sinon who signed the contract with Yooni Kim, MD, Asia Executive Director of Novotech. Rodmar C. Pulido, Department Manager of MakatiMeds Clinical Research Center, and Jennifer Olive Arellano, Novotechs Country Head in the Philippines, also witnessed the MOU signing.
For more information, please contact MakatiMed On-Call at +632.8888 999, email email@example.com, or visit www.makatimed.net.ph.